[시장보고서]핵의학 시장 : 유형별(진단 및 치료), 용도별, 최종사용자별, 지역별 예측(-2032년)

핵의학 시장 : 유형별(진단 및 치료), 용도별, 최종사용자별, 지역별 예측(-2032년)

Global Nuclear Medicine Market Research Report Information by Type (Diagnosis and Therapeutic ), by Application, by End User, and by Region - Forecast till 2032

상품코드 : 1565596 해당 상품은 즉시 배송 가능합니다

리서치사 : Market Research Future

발행일 : 2024년 08월

페이지 정보 : 영문 200 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,950

￦ 7,344,000

PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste 가능합니다.

US $ 5,950

￦ 8,828,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 기업 내 10명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste 가능합니다.

US $ 7,250

￦ 10,756,000

PDF & Excel (Enterprise License)

PDF, Excel 보고서를 동일 기업이 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste 가능하며, 인쇄 가능합니다.

한글목차

샘플 요청 목록에 추가

세계 핵의학 시장 규모는 2023년 98억 4,000만 달러, 2024년 106억 3,000만 달러에서 2032년 279억 6,000만 달러 규모로 성장할 것으로 예측됩니다.

핵의학 기술 발전과 헬스케어 산업에서 방사성 동위원소의 사용 확대가 시장 성장의 주요 요인으로 작용하고 있습니다. 또한, 새로운 기술의 R&D를 위한 민관 투자 확대와 갑상선 관련 질환, 호흡기질환, 뼈 질환, 신경 질환 등의 정확한 진단을 위한 방사선 치료를 개선하기 위한 R&D의 증가도 시장 성장을 견인하고 있습니다.

지역별 전망

북미는 제품 접근성이 용이하고 시장 진입이 활발해 2023년 42.42%로 가장 큰 시장 점유율을 차지했습니다. 유럽 시장은 심장병, 알츠하이머병, 신경질환 환자 증가와 진단 및 치료 프로세스 개선에 대한 수요 증가로 인해 예측 기간 동안 큰 폭의 성장이 예상됩니다. 또한, 강화된 방사성의약품의 채택, 신제품 도입, M&A로 인해 이 지역 시장은 확대되고 있습니다. 아시아태평양은 심장병 환자 증가와 PET, SPECT 등 첨단 영상 진단 기술 시장 개척으로 빠른 성장이 예상됩니다. 또한, 감마 카메라를 사용하여 SPECT 영상 기술을 구현하기 위해 임상의가 여러 2D 및 3D 이미지에 쉽게 접근할 수 있게 됨에 따라 이 지역의 핵의학 시장을 촉진하고 있습니다.

세계 핵의학 시장을 조사했으며, 시장의 정의와 개요, 시장 성장에 영향을 미치는 각종 영향요인 분석, 시장 규모 추정 및 예측, 각종 부문별·지역별 분석, 경쟁 환경, 주요 기업 프로파일 등의 정보를 정리하여 전해드립니다.

영문목차

Global Nuclear Medicine Market Research Report Information by Type (Diagnosis [SPECT Radiopharmaceuticals {Tc99m, I-123, and Others} and PET Radiopharmaceuticals {F18, C11 Choline, and Others}] and Therapeutic (Alpha Emitters [Actinium-225 (Ac-225), Radium-223 (Ra-223), and Others], Beta Emitters [Yttrium-90 (Y-90), Lutetium-177 (Lu-177), and Others], and Brachytherapy Isotopes [Iodine-125 (I-125) and Others]), by Application (Neurology, Cardiology, Oncology [Prostate Cancer, Breast Cancer, Lung and Bronchus Cancer, Thyroid Cancer, Colorectal Cancer, and Others], and Others), by End User (Hospitals & Diagnostic Centers, Research Institutes, and Others), and by Region (North America, Europe, Asia-Pacific, and Rest of the World) - Forecast till 2032

Market Overview

In 2023, the nuclear medicine market was estimated to be worth USD 9.84 billion. The Nuclear Medicine Market industry is anticipated to expand from USD 10.63 billion in 2024 to USD 27.96 billion by 2032. Technological advancements in nuclear medicine and the increasing applications of radioisotopes in the healthcare industry are the primary factors driving market growth. Additionally, the nuclear medicine market is being driven by the expansion of public-private funding for the research and development of new techniques, as well as the increasing research and development in the pharmaceutical and biotechnology industries to improve radiotherapy for the accurate diagnosis of diseases such as thyroid-related diseases, respiratory diseases, bone diseases, neurological diseases, and others.

Market segment insights

The Nuclear Medicine Market has been divided into two categories: diagnostic and therapeutic. The Nuclear Medicine Market has been segmented into neurology, cardiology, oncology, and other fields based on application. The Nuclear Medicine Market has been categorized as hospitals & diagnostic centers, research institutes, and others based on the end user.

Regional Perspectives

The market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World by region. As a result of the availability of products and the presence of active industry participants in the region, North America accounted for the largest market share of 42.42% in 2023. The European market is expected to experience substantial growth during the forecast period because of the growing number of individuals suffering from heart disease, Alzheimer's disease, and neurological problems, as well as the increasing demand for improved diagnostic and treatment processes. Additionally, the nuclear medicine market is expanding because of the adoption of enhanced radiopharmaceuticals, new product introductions, and mergers and acquisitions. The market in Asia-Pacific is expected to experience rapid growth because of the increasing number of cardiac patients and the development of advanced imaging techniques that utilize diagnostic instruments such as PET and SPECT. Additionally, clinicians are being facilitated in their access to multiple 2D and 3D images using a gamma camera to perform SPECT imaging techniques, which is propelling the nuclear medicine market in the region. Moreover, the nuclear medicine market in Japan accounted for the largest market share in 2023, while the nuclear medicine market in India is the fastest-growing market in the Asia-Pacific region.

Major Players

Novartis AG (Switzerland), GE Healthcare (US), Cardinal Health (US), Eckert & Ziegler Group (Germany), Lantheus (US), Jubilant Radiopharma (Canada), Bayer AG (Germany), Siemens Healthineers (Germany), Curium Pharma (France), Bracco (Italy), and others are among the key companies in the Nuclear Medicine Market.

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

3.1 OVERVIEW
3.2 DATA FLOW
- 3.2.1 DATA MINING PROCESS
3.3 PURCHASED DATABASE:
3.4 SECONDARY SOURCES:
- 3.4.1 SECONDARY RESEARCH DATA FLOW:
3.5 PRIMARY RESEARCH:
- 3.5.1 PRIMARY RESEARCH DATA FLOW:
- 3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED
- 3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE
3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
- 3.6.1 REVENUE ANALYSIS APPROACH
3.7 DATA FORECASTING
- 3.7.1 DATA FORECASTING TYPE
3.8 DATA MODELING
- 3.8.1 MICROECONOMIC FACTOR ANALYSIS:
- 3.8.2 DATA MODELING:
3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

4.1 INTRODUCTION
4.2 DRIVERS
- 4.2.1 RISING PREVALENCE OF CANCER AND OTHER CHRONIC DISEASES
- 4.2.2 TECHNOLOGICAL ADVANCEMENTS IN NUCLEAR MEDICINE
4.3 RESTRAINTS
- 4.3.1 SHORT HALF-LIFE OF RADIOPHARMACEUTICALS
- 4.3.2 SHORTAGE OF TRAINED MEDICAL PERSONNEL
4.4 OPPORTUNITY
- 4.4.1 USE OF RADIOPHARMACEUTICALS IN NEUROLOGICAL APPLICATIONS

5 MARKET FACTOR ANALYSIS

5.1 PORTER'S FIVE FORCES MODEL
- 5.1.1 THREAT OF NEW ENTRANTS
- 5.1.2 BARGAINING POWER OF SUPPLIERS
- 5.1.3 THREAT OF SUBSTITUTES
- 5.1.4 BARGAINING POWER OF BUYERS
- 5.1.5 INTENSITY OF RIVALRY
5.2 IMPACT OF COVID-19 ON THE GLOBAL NUCLEAR MEDICINE MARKET

6 GLOBAL NUCLEAR MEDICINE MARKET, BY TYPE

6.1 OVERVIEW
6.2 DIAGNOSTIC
- 6.2.1 SPECT RADIOPHARMACEUTICALS
  - 6.2.1.1 MO99/TC99M
  - 6.2.1.2 I-123
  - 6.2.1.3 OTHERS
- 6.2.2 PET RADIOPHARMACEUTICALS
  - 6.2.2.1 F18
  - 6.2.2.2 C11 CHOLINE
  - 6.2.2.3 OTHERS
6.3 THERAPEUTIC
- 6.3.1 ALPHA EMITTERS
  - 6.3.1.1 ACTINIUM-225 (AC-225)
  - 6.3.1.2 RADIUM-223 (RA-223)
  - 6.3.1.3 OTHERS
- 6.3.2 BETA EMITTERS
  - 6.3.2.1 YTTRIUM-90 (Y-90)
  - 6.3.2.2 LUTETIUM-177 (LU-177)
  - 6.3.2.3 OTHERS
- 6.3.3 BRACHYTHERAPY ISOTOPE
  - 6.3.3.1 IODINE-125 (I-125)
  - 6.3.3.2 OTHERS

7 GLOBAL NUCLEAR MEDICINE MARKET, BY APPLICATION

7.1 OVERVIEW
7.2 NEUROLOGY
7.3 CARDIOLOGY
7.4 ONCOLOGY
- 7.4.1 PROSTATE CANCER
- 7.4.2 BREAST CANCER
- 7.4.3 LUNG AND BRONCHUS CANCER
- 7.4.4 THYROID CANCER
- 7.4.5 COLORECTAL CANCER
- 7.4.6 OTHERS
7.5 OTHERS

8 GLOBAL NUCLEAR MEDICINE MARKET, BY END USER

8.1 OVERVIEW
8.2 HOSPITALS AND DIAGNOSTIC CENTERS
8.3 RESEARCH INSTITUTES
8.4 OTHERS

9 GLOBAL NUCLEAR MEDICINE MARKET, BY REGION

9.1 OVERVIEW
9.2 NORTH AMERICA
- 9.2.1 US
- 9.2.2 CANADA
- 9.2.3 MEXICO
9.3 EUROPE
- 9.3.1 GERMANY
- 9.3.2 FRANCE
- 9.3.3 UK
- 9.3.4 ITALY
- 9.3.5 SPAIN
- 9.3.6 REST OF EUROPE
9.4 ASIA-PACIFIC
- 9.4.1 CHINA
- 9.4.2 INDIA
- 9.4.3 JAPAN
- 9.4.4 SOUTH KOREA
- 9.4.5 AUSTRALIA
- 9.4.6 REST OF ASIA-PACIFIC
9.5 REST OF THE WORLD
- 9.5.1 MIDDLE EAST & AFRICA
- 9.5.2 SOUTH AMERICA

10 COMPETITIVE LANDSCAPE

10.1 INTRODUCTION
10.2 MARKET SHARE ANALYSIS,
10.3 COMPETITOR DASHBOARD
10.4 PUBLIC PLAYERS STOCK SUMMARY
10.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 10.6.1 PRODUCT LAUNCH / PRODUCT APPROVAL
- 10.6.2 PARTNERSHIP
- 10.6.3 ACQUISITION
- 10.6.4 AGREEMENT
- 10.6.5 COLLABORATION
- 10.6.6 EXPANSION

11 COMPANY PROFILES

11.1 GE HEALTHCARE
- 11.1.1 COMPANY OVERVIEW
- 11.1.2 FINANCIAL OVERVIEW
- 11.1.3 PRODUCTS/SERVICES OFFERED
- 11.1.4 KEY DEVELOPMENTS
- 11.1.5 SWOT ANALYSIS
- 11.1.6 KEY STRATEGIES
11.2 CARDINAL HEALTH
- 11.2.1 COMPANY OVERVIEW
- 11.2.2 FINANCIAL OVERVIEW
- 11.2.3 PRODUCTS OFFERED
- 11.2.4 KEY DEVELOPMENTS
- 11.2.5 SWOT ANALYSIS
- 11.2.6 KEY STRATEGIES
11.3 CURIUM
- 11.3.1 COMPANY OVERVIEW
- 11.3.2 FINANCIAL OVERVIEW
- 11.3.3 PRODUCTS OFFERED
- 11.3.4 KEY DEVELOPMENTS
- 11.3.5 KEY STRATEGIES
11.4 NOVARTIS AG
- 11.4.1 COMPANY OVERVIEW
- 11.4.2 FINANCIAL OVERVIEW
- 11.4.3 PRODUCTS OFFERED
- 11.4.4 KEY DEVELOPMENTS
- 11.4.5 SWOT ANALYSIS
- 11.4.6 KEY STRATEGIES
11.5 LANTHEUS
- 11.5.1 COMPANY OVERVIEW
- 11.5.2 FINANCIAL OVERVIEW
- 11.5.3 PRODUCTS OFFERED
- 11.5.4 KEY DEVELOPMENTS
- 11.5.5 KEY STRATEGIES
11.6 JUBILANT RADIOPHARMA
- 11.6.1 COMPANY OVERVIEW
- 11.6.2 FINANCIAL OVERVIEW
- 11.6.3 PRODUCTS OFFERED
- 11.6.4 KEY DEVELOPMENTS
- 11.6.5 KEY STRATEGIES
11.7 SIEMENS HEALTHINEERS
- 11.7.1 COMPANY OVERVIEW
- 11.7.2 FINANCIAL OVERVIEW
- 11.7.3 PRODUCTS OFFERED
- 11.7.4 KEY DEVELOPMENTS
- 11.7.5 SWOT ANALYSIS
- 11.7.6 KEY STRATEGIES
11.8 BAYER AG
- 11.8.1 COMPANY OVERVIEW
- 11.8.2 FINANCIAL OVERVIEW
- 11.8.3 PRODUCTS OFFERED
- 11.8.4 KEY DEVELOPMENTS
- 11.8.5 SWOT ANALYSIS
- 11.8.6 KEY STRATEGY
11.9 ECKERT & ZIEGLER
- 11.9.1 COMPANY OVERVIEW
- 11.9.2 FINANCIAL OVERVIEW
- 11.9.3 PRODUCTS OFFERED
- 11.9.4 KEY DEVELOPMENTS
- 11.9.5 KEY STRATEGIES
11.10 BRACCO
- 11.10.1 COMPANY OVERVIEW
- 11.10.2 FINANCIAL OVERVIEW
- 11.10.3 PRODUCTS OFFERED
- 11.10.4 KEY DEVELOPMENTS
- 11.10.5 KEY STRATEGY

한글목차

목차

제1장 주요 요약

제2장 시장 개요

제3장 조사 방법

제4장 시장 역학

제5장 시장 요인 분석

제6장 세계의 핵의학 시장 : 유형별

제7장 세계의 핵의학 시장 : 용도별

제8장 세계의 핵의학 시장 : 최종사용자별

제9장 세계의 핵의학 시장 : 지역별

제10장 경쟁 상황

제11장 기업 개요

제12장 데이터 인용